During the 2018 American Society of Clinical Oncology Annual Meeting, researchers published new findings on the use of rituximab in mantle cell lymphoma (MCL) as well as the outcomes of patients who relapse early after treatment with rituximab for diffuse large B-cell lymphoma (DLBCL).
During the 2018 American Society of Clinical Oncology Annual Meeting, researchers published new findings on the use of rituximab in mantle cell lymphoma (MCL) as well as the outcomes of patients who relapse early after treatment with rituximab for diffuse large B-cell lymphoma (DLBCL).
Rituximab is not currently approved—but is sometimes used off-label—for maintenance therapy in MCL, but this use is not well studied. A systematic review and meta-analysis, published in an abstract, evaluated the outcomes of patients given rituximab maintenance versus patients not given rituximab maintenance, with outcomes of interest including progression-free survival (PFS) and overall survival (OS).1
The researchers assessed 7 studies (including a total of 1050 patients). Three of the studies were randomized controlled trials (RCTs) and 4 were observational studies with comparative arms. Across tstudies, 455 patients received rituximab maintenance and 595 did not.
Overall, rituximab maintenance improved PFS (HR, 0.39; 95% CI, 0.31-0.50) and OS (HR, 0.47; 95% CI, 0.27-0.83), and these results persisted when assessing only patients treated after autologous stem cell transplantation for both PFS (HR, 0.34; 95% CI, 0.25-0.47) and OS (HR, 0.38; 95% CI, 0.22-0.65).
When restricting the analysis to prospective RCTs, rituximab maintenance improved PFS (HR 0.47; 95% CI, 0.34-0.65) but not OS (HR, 0.70; 95% CI, 0.46-1.08). Only 2 of the 3 RCTs reported OS, however.
Another study on rituximab discussed the biologic’s use in DLBCL, a disease that has a relapse rate of approximately 40%.2 The study’s authors compared the clinical features and outcomes of patients from the Singapore lymphoma study database who experienced early relapse (within 2 years), late relapse (after 2 years), and continuous complete remission (no relapse after 5 years) following treatment with rituximab and chemotherapy received between 1992 and 2017.
Of 472 total patients, 135 had early relapse, 42 had late relapse, and 295 had continuous complete remission. In the 2 relapse groups, median survival was 1.4 years (range, 1.16-1.83), and 9.86 years (range, 6.86-13.31).
The researchers found that 98% of patients with residual disease at the end of treatment with rituximab and chemotherapy had an early relapse, and the odds of early relapse versus late relapse was higher in patients with high levels of lactate dehydrogenase, more than 1 extranodal site of disease, and stage III or stage IV disease (though age over 60 years or central nervous system involvement were not associated with early relapse).
The researchers say that, even in the era of rituximab, patients with early relapse have worse outcomes, and clinical factors predict these poor outcomes.
References
1. Hilal T, Wang Z, Almader-Douglas D, et al. Rituximab maintenance for mantle cell lymphoma: a meta-analysis. J Clin Oncol. 2018;36(suppl; Abstract e19557).
2. Koh JJ, Lim ST, Sultana R, et al. Predictors of early vs late diffuse large B cell lymphoma (DLBCL) relapses in the rituximab era. J Clin Oncol. 2018;36(suppl; Abstract e19553).
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.